Vaccine Companies See Stock Decline After Trump's Health Secretary Pick

Robert F. Kennedy Jr.'s nomination raises concerns due to his anti-vaccine stance, impacting pharmaceutical markets.

Stocks of major vaccine producers like Moderna, Pfizer, and BioNTech fell significantly following the announcement of Robert F. Kennedy Jr. as the new Health Secretary.
Kennedy Jr., known for his controversial views on vaccines, is set to lead a department with a $1.7 trillion budget overseeing crucial health agencies.
European pharmaceutical companies, including AstraZeneca and Sanofi, also experienced stock declines amid investor uncertainty.
Kennedy Jr.'s appointment is seen as a bold move by Trump, reflecting their recent political alliance and shared skepticism towards established health policies.
Public health experts express concern over potential impacts on vaccination rates and health policy direction in the United States.